Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.

Literature DB >> 6487513

Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.

J Barre, G Houin, J Rosenbaum, R Zini, D Dhumeaux, J P Tillement.

Abstract

Entities: Disease

Mesh：

Substances：
Orosomucoid
Erythromycin

Year: 1984 PMID： 6487513 PMCID： PMC1463634 DOI： 10.1111/j.1365-2125.1984.tb02525.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

5 in total

Review 1. Disease-induced changes in the plasma binding of basic drugs.

Authors: K M Piafsky
Journal: Clin Pharmacokinet Date: 1980 May-Jun Impact factor: 6.447

2. Measurement of serum alpha 1-acid glycoprotein and alpha 1-antitrypsin desialylation in liver disease.

Authors: N Serbource-Goguel; M Corbic; S Erlinger; G Durand; J Agneray; J Feger
Journal: Hepatology Date: 1983 May-Jun Impact factor: 17.425

3. Intersubject and dose-related variability after intravenous administration of erythromycin.

Authors: K L Austin; L E Mather; C R Philpot; P J McDonald
Journal: Br J Clin Pharmacol Date: 1980-09 Impact factor: 4.335

4. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors: K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal: N Engl J Med Date: 1978-12-28 Impact factor: 91.245

5. Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma.

Authors: L F Chio; C J Oon
Journal: Cancer Date: 1979-02 Impact factor: 6.860

5 in total

12 in total

Review 1. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors: R Zini; P Riant; J Barré; J P Tillement
Journal: Clin Pharmacokinet Date: 1990-09 Impact factor: 6.447

2. Drug-binding proteins in liver transplant patients.

Authors: M L Huang; R Venkataramanan; G J Burckart; R J Ptachcinski; D H Van Thiel; T E Starzl
Journal: J Clin Pharmacol Date: 1988-06 Impact factor: 3.126

3. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.

Authors: L E Pedersen; J Bonde; N A Graudal; N V Backer; J E Hansen; J P Kampmann
Journal: Br J Clin Pharmacol Date: 1987-01 Impact factor: 4.335

4. The plasma protein binding of basic drugs.

Authors: P A Routledge
Journal: Br J Clin Pharmacol Date: 1986-11 Impact factor: 4.335

5. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

Authors: J Barre; A Mallat; J Rosenbaum; L Deforges; G Houin; D Dhumeaux; J P Tillement
Journal: Br J Clin Pharmacol Date: 1987-06 Impact factor: 4.335

6. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Authors: E Snoeck; A Van Peer; M Sack; M Horton; G Mannens; R Woestenborghs; R Meibach; J Heykants
Journal: Psychopharmacology (Berl) Date: 1995-12 Impact factor: 4.530

7. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.

Authors: A Baruzzi; M Contin; E Perucca; F Albani; R Riva
Journal: Eur J Clin Pharmacol Date: 1986 Impact factor: 2.953